Improvements in fatigue and oxidative stress

In a clinical study of 80 CFS sufferers, 38 were given Robuvit® for six months, with the remaining 42 serving as controls. Participants were evaluated using the Multidimensional Assessment of Fatigue (MAF) questionnaire developed by the University of Washington. Results clearly showed improvements in fatigue and oxidative stress in those taking Robuvit®.

A human study involving 91 subjects, published in the journal Panminerva Medica in March 2014, had previously identified all Robuvit®'s properties. In this six-month study, 48 subjects were given 200mg of Robuvit® a day, with 43 serving as controls. Specific CFS questionnaires, as well as the Brief Mood Introspection Scale (BMIS), were used to assess mood variations in CFS patients. Participants had to have at least five CFS symptoms to be included in the study. Researchers also measured oxidative stress and found increased levels in 61 of the 91 subjects. The assessment was repeated at 3 and 6 months. The study showed that taking Robuvit® produced reductions in primary CFS symptoms.

• 18 % in weakness and exhaustion.
• 44 % in sleep problems.
• 29 % in short-term memory loss.
• 62 % in muscle pain.
• 51 % in joint pain.
• 33 % in headaches and neuralgia.
• 47 % in swollen glands in the neck and armpits.

Antihistaminic effects

Notable decreases in secondary symptoms were also observed, particularly in hypersensitivity (to noise, diet, drugs), dizziness, depression, weight changes, mood swings and allergies. Allergies and hypersensitivity as CFS symptoms were recently investigated in a human study involving 30 female volunteers - 14 in a control group and 16 in a test group – in which the effects of Robuvit® supplementation on cutaneous reactions (redness and swelling) were evaluated. The supplemented volunteers were given 300mg of Robuvit® a day for three days plus an intracutaneous injection of histamine. At the end of the three days, researchers observed a significant reduction in the histamine-induced swelling and redness in the test group, indicating an antihistamine effect for Robuvit®.

Antioxidant potency

Robuvit® also has significant antioxidant activity and acts at a sub-clinical, cellular level, distinguishing it from other products which simply tackle symptoms. Its antioxidant properties were highlighted in a pilot study which evaluated markers of oxidative stress, antioxidant enzyme activity (SOD, catalase, glutathione peroxidase) and total antioxidant capacity in plasma. Scientists found that a daily dose of 300mg for one month significantly reduced serum levels of Advanced Oxidation Protein Products (AOPP) and lipid peroxides, and noticeably increased total antioxidant capacity in plasma. In a 12-week, placebo-controlled study of 61 patients (32 receiving Robuvit® and 29 controls), a 200mg daily dose of Robuvit® (or 300mg/day for those weighing over 80 kilos) normalised levels of ASAT, ALAT, alkaline phosphatase and gamma GT, and reduced plasma oxidative stress.

A small, eight-week pilot study has just been published which suggests that a 300-600mg daily dose of Robuvit® may reduce lymphoedema in legs and improve microcirculation and tissue oxygenation.

Royal jelly combines well with other substances available to buy at Supersmart such as ginseng, green propolis, Robuvit®, a French oak extract used for reducing fatigue, and Asc2P 250 mg, a potent and stable form of vitamin C.

There is no need to refrigerate freeze-dried royal jelly.

Everyone can benefit from royal jelly, but it may be particularly useful for sportspeople, pregnant women, the over-40s, delicate individuals and those suffering from fatigue or recurrent illness.